Financial giants have made a conspicuous bearish move on SpringWorks Therapeutics. Our analysis of options history for ...

The clinical-stage biopharmaceutical company saw the highest jump in retail interest after reporting positive topline data ...

Shares of SpringWorks Therapeutics SWTX have rallied 32.9% in the past three months compared with the industry’s increase of ...

SpringWorks Therapeutics is working on new potential indications for its IP portfolio while running additional trials. See ...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Free Report) saw some unusual options trading on Thursday. Traders acquired 13,068 call options on the stock. This is an increase of 223% compared to ...

Our analysis of options history for SpringWorks Therapeutics SWTX revealed 9 unusual trades. Delving into the details, we ...

【德国默克就收购美国生物技术公司 SpringWorks 进行深入谈判】德国医疗保健和技术集团默克公司周一表示，该公司正在 就收购美国癌症和罕见病制药商SpringWorks Therapeutics进行深入谈判。默克公司在声明中说，收购SpringWorks的谈判正在进行中。这家总部位于德国达姆施塔特（Darmstadt）的公司表示，尚未签署任何具有法律约束力的协议，也不确定交易是否会实现。

While the company is in discussions to acquire SpringWorks, it did not elaborate on these talks in its earnings call.

On February 10, 2025, the Group confirmed advanced discussions about a potential acquisition of SpringWorks Therapeutics ( SWTX ), Inc., USA. At the time of the preparation of the Consolidated ...

Barclays analyst Peter Lawson says SpringWorks Therapeutics (SWTX) this morning cancelled from the firm’s conference next week, following ...

Ahead of Merck KGaA’s earnings announcement Thursday, investors were mostly looking forward to any comments about its ...

Oppenheimer Asset Management Inc. lessened its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report) by 6.2% in ...